FDA Moves to Permanently End 503B GLP-1 Compounding
FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list — permanently ending outsourcing-facility compounding if finalized.
May 15, 2026 · 3 min read
The FDA published a proposed rule on April 30, 2026 that would formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances list — a regulatory action that, if finalized, would permanently prohibit large outsourcing facilities from compounding these drugs from bulk substances under any circumstances, including during future shortage declarations.
The public comment period runs through June 29, 2026. After that, the FDA will review comments and issue a final determination.
What the 503B Bulks List Is
Section 503B of the Federal Food, Drug, and Cosmetic Act governs outsourcing facilities — large compounders that produce significant volumes of drugs without individual prescriptions. These are distinct from 503A pharmacies, which compound smaller quantities under patient-specific prescriptions.
During the 2022–2025 period when semaglutide and tirzepatide appeared on the FDA shortage list, 503B outsourcing facilities were permitted to compound these drugs in bulk under enforcement discretion, since the branded drugs were genuinely unavailable.
The shortage designations ended: tirzepatide was removed from the shortage list in December 2024; semaglutide was removed in February 2025.
The new proposed rule goes further than simply ending shortage-era discretion. By proposing to formally exclude these three drugs from the 503B bulks list, the FDA would eliminate any future pathway for 503B compounding of GLP-1 drugs — even if a new shortage were declared. The legal standard for 503B bulk compounding requires demonstrated "clinical need," and the FDA determined no such need exists for these agents given the availability of approved branded formulations.
Why It Matters
For the roughly 1–2 million Americans who currently source compounded semaglutide or tirzepatide from 503B outsourcing facilities, this rule represents a formal end of the road. Many of these patients chose compounded formulations for cost reasons — compounded semaglutide typically runs $150–400 per month versus $1,000+ for Wegovy or Ozempic without insurance.
The FDA cited more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from patients self-administering from multidose vials, in some cases requiring hospitalization.
The rule does not affect 503A pharmacies, which compound patient-specific prescriptions. 503A pharmacies have a different legal framework and are not covered by this proposed rule. Whether 503A compounding of GLP-1 drugs continues to be permitted is a separate regulatory question the FDA has not yet resolved in the same way.
What to Watch
The comment period is the immediate action item for patients, prescribers, and compounding advocates. Legal challenges are widely expected if the rule is finalized — compounding trade groups have previously challenged FDA enforcement actions on semaglutide and tirzepatide in federal court, with mixed results.
For patients currently on compounded GLP-1 therapy: this rule is proposed, not final. Nothing changes until a final rule is issued, which would require the FDA to review all comments and could take months. However, planning for a transition to a covered branded product — or exploring direct-pay options — is now a prudent step rather than a wait-and-see.
The June 29, 2026 comment deadline is the practical deadline to watch.
Sources
Sources
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (FDA press release)
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B (Federal Register)
- FDA says 'no clinical need' for compounded weight loss drugs (STAT News)
- FDA Moves to Permanently Close the Door on Compounded GLP-1s (Pharmacy Times)